Investor Relations

Company Overview

Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company. At Alzamend, we are committed to “Making Alzheimer’s Just a Memory™ ” as well as developing effective treatments for psychiatric disorders which effect over 600 million people globally. Our mission is to rapidly develop and market safe and effective treatments. We are driven by the belief that strong support of research is the foundation for true innovation and uniquely position us to understand and effectively address the unmet needs of the patients we serve. Alzamend strives to provide hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.

Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Our lead product candidate(AL001) that we have licensed and have begun clinical development in humans for the treatment of Alzheimer’s, bipolar disorder, MDD and PTSD. Based on our preclinical data, AL001 treatment prevents cognitive deficits, depression and irritability in APPSWE/PS1dE9 mice, and is superior in improving associative learning, memory, and irritability, compared with lithium carbonate treatments. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially mitigating the regulatory burden for safety data.

Stock Snapshot

Latest Financial Results

Q3 2023

Quarter Ended Jan 31, 2023

Latest Annual Filing

For Fiscal Year Ending Apr 30, 2022

Latest Presentation

Alzamend - Corporate Presentation

Upcoming Event

2023 Annual Meeting of Stockholders

IR Contacts


Alzamend Neuro, Inc.
3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
T: 844-722-6333

Transfer Agent

Computershare Trust Company, N.A.
150 Royall Street
Canton, MA 02021

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Skip to content